

## [Amoxicillin + clavulanic acid](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.2. Antibacterials](#) [6.2.5. Antituberculosis medicines](#)

ATC codes: [J01CR02](#)

EMLc

Indication

Multi-drug resistant Mycobacterium tuberculosis ICD11 code: [ML32.00](#)

INN

Amoxicillin + clavulanic acid

Medicine type

Chemical agent

Antibiotic groups

[ACCESS](#)

List type

Core

Additional notes

For use only in combination with meropenem or imipenem + cilastatin (EML). For use only in combination with meropenem (EMLc)

Formulations

**Oral > Liquid:** 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid (EMLc)

**Oral > Solid > dispersible tablet:** 250 (as trihydrate) + 62.5 (as potassium salt) (EMLc)

**Oral > Solid > tablet:** 500 mg (as trihydrate) + 125 mg (as potassium salt)

EML status history

First added in 2019 ([TRS 1021](#))

Changed in 2021 ([TRS 1035](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Amoxicillin + clavulanic acid](#)

DrugBank

[Amoxicillin](#),

[Clavulanic acid \(Clavulanate\)](#)

Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the transfer of listings for medicines for multi-drug resistant tuberculosis from the complementary to the core list of the EML and EMLc. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of amoxicillin + clavulanic acid 250 mg + 62.5 mg dispersible tablets to the EMLc.